Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | WNT3 | P56703 | 1/20 | 0.44 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.44 |
| ▸ | ELOVL6 | Q9H5J4 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873198 | 0.92 | LMNA (0.47) | LMNAHTR2AKCNH2HTR2CSPR | |
| SCHEMBL14227531 | 0.82 | HTR2A (0.51) | LMNAHTR2AKCNH2HTR2CSPR | |
| SCHEMBL17689403 | 0.80 | HTR2A (0.55) | HTR2AKCNH2HTR2CSPRDRD2 | |
| SCHEMBL27917812 | 0.79 | HTR2A (0.58) | HTR2AKCNH2HTR2CSPRSMN1; SMN2 | |
| SCHEMBL13947675 | 0.78 | GPR119 (0.59) | PKM | |
| SCHEMBL14413086 | 0.77 | HTR2A (0.55) | HTR2AKCNH2HTR2CSPRSMN1; SMN2 | |
| SCHEMBL14242442 | 0.76 | BLM (0.55) | HTR2AKCNH2HTR2CSPRSMN1; SMN2 | |
| SCHEMBL13873506 | 0.75 | HTR2A (0.62) | HTR2AKCNH2HTR2C | |
| SCHEMBL13873709 | 0.75 | TAAR1 (0.49) | LMNAHTR2AKCNH2HTR2CSPR | |
| SCHEMBL13873193 | 0.75 | ALDH1A1 (0.55) | LMNAWNT3SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | LMNA 3647/4885HTR2A 4228/4885KCNH2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.